(Total Views: 571)
Posted On: 01/07/2021 3:10:27 PM
Post# of 145879
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Re: MD VIROLOGIST #71735
Quote:
Someone asked LL vs. Mav binding affinity to the receptor, Mav binds more avidly and can even displace LL. From BP.
Quote:
Occupancy of CCR5 receptors by maraviroc was studied in HIV-1–infected patients and was found to be >80% just before readministration at a steady state. Five days after discontinuation of the drug, the receptors remained >60% occupied
[https://academic.oup.com/cid/article/47/2/236/358070]https://academic.oup.com/cid/article/47/2/236/358070[/url]
With superior occupancy one would think it would have superior efficacy to leronlimab.
Quote:
At week 48, 67.3% maraviroc (=ART) recipients and 76.3% placebo (+ART) recipients achieved an undetectable viral load (VL <50 copies/mL; P=0.048).
https://www.jwatch.org/na50863/2020/02/21/can...vanced-hiv
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)